stereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. these innovations help physicians provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. over 100 issued patents support the stereotaxis platform. the core components of stereotaxis’ systems have received regulatory clearance in the united states, european union, japan, canada, china, and elsewhere. for more information, please visit www.stereotaxis.com.
Company profile
Ticker
STXS
Exchange
Website
CEO
David Fischel
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Medtronic • Varian Medical Systems • Conmed • Integer • Masimo • Natus Medical • LivaNova • BioPlus Acquisition • QT Imaging • Outset Medical ...
SEC CIK
Corporate docs
IRS number
943120386
STXS stock data
Latest filings (excl ownership)
DEFA14A
Additional proxy soliciting materials
8 Apr 24
DEFA14A
Additional proxy soliciting materials
4 Apr 24
DEF 14A
Definitive proxy
4 Apr 24
10-K
2023 FY
Annual report
8 Mar 24
8-K
Stereotaxis Reports 2023 Full Year Financial Results
4 Mar 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
Stereotaxis Reports 2023 Third Quarter Financial Results
9 Nov 23
10-Q
2023 Q2
Quarterly report
11 Aug 23
8-K
Stereotaxis Reports 2023 Second Quarter Financial Results
10 Aug 23
8-K
Other Events
15 Jun 23
Transcripts
STXS
Earnings call transcript
2023 Q4
4 Mar 24
STXS
Earnings call transcript
2023 Q3
9 Nov 23
STXS
Earnings call transcript
2023 Q2
10 Aug 23
STXS
Earnings call transcript
2023 Q1
9 May 23
STXS
Earnings call transcript
2022 Q4
3 Mar 23
STXS
Earnings call transcript
2022 Q3
10 Nov 22
STXS
Earnings call transcript
2022 Q2
9 Aug 22
STXS
Earnings call transcript
2022 Q1
10 May 22
STXS
Earnings call transcript
2021 Q4
3 Mar 22
STXS
Earnings call transcript
2021 Q3
11 Nov 21
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 22.98 mm | 22.98 mm | 22.98 mm | 22.98 mm | 22.98 mm | 22.98 mm |
Cash burn (monthly) | 317.33 k | 788.00 k | 1.88 mm | 1.75 mm | 322.33 k | 771.00 k |
Cash used (since last report) | 2.15 mm | 5.35 mm | 12.76 mm | 11.88 mm | 2.19 mm | 5.24 mm |
Cash remaining | 20.82 mm | 17.62 mm | 10.21 mm | 11.10 mm | 20.79 mm | 17.74 mm |
Runway (months of cash) | 65.6 | 22.4 | 5.4 | 6.3 | 64.5 | 23.0 |
Institutional ownership, Q3 2023
45.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 56 |
Opened positions | 4 |
Closed positions | 7 |
Increased positions | 17 |
Reduced positions | 17 |
13F shares | Current |
---|---|
Total value | 59.02 bn |
Total shares | 37.39 mm |
Total puts | 2.10 k |
Total calls | 1.00 k |
Total put/call ratio | 2.1 |
Largest owners | Shares | Value |
---|---|---|
DAFNA Capital Management | 13.68 mm | $21.62 bn |
Redmile | 5.77 mm | $9.11 bn |
Lagoda Investment Management | 3.25 mm | $5.13 bn |
Arbiter Partners Capital Management | 2.68 mm | $4.23 bn |
Archon Capital Management | 2.68 mm | $4.23 bn |
Vanguard | 2.18 mm | $3.45 bn |
Essex Investment Management | 1.31 mm | $2.07 bn |
BLK Blackrock | 1.07 mm | $1.69 bn |
Prescott Group Capital Management, L.L.C. | 722.72 k | $1.14 bn |
AlphaCentric Advisors | 600.00 k | $948.00 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 Apr 24 | Peery Kimberly R. | Stock Options -Right to Buy Common Stock | Grant | Acquire A | No | No | 3.01 | 40,000 | 120.40 k | 250,750 |
2 Jan 24 | Fischel Nathan | Common Stock | Grant | Acquire A | No | No | 0 | 64,935 | 0.00 | 477,084 |
2 Jan 24 | Messey Robert J | Common Stock | Grant | Acquire A | No | No | 0 | 64,935 | 0.00 | 518,402 |
2 Jan 24 | Curet Myriam | Common Stock | Grant | Acquire A | No | No | 0 | 64,935 | 0.00 | 191,470 |
2 Jan 24 | Benfer David | Common Stock | Grant | Acquire A | No | No | 0 | 64,935 | 0.00 | 315,284 |
News
Lake Street Maintains Buy on Stereotaxis, Raises Price Target to $4
5 Mar 24
Roth MKM Reiterates Buy on Stereotaxis, Maintains $5 Price Target
5 Mar 24
12 Health Care Stocks Moving In Monday's After-Market Session
4 Mar 24
Recap: Stereotaxis Q4 Earnings
4 Mar 24
Stereotaxis Q4 2023 GAAP EPS $(0.070), Inline, Sales $4.565M Miss $7.700M Estimate
4 Mar 24